Routine noninvasive prenatal screening for fetal <i>RHD</i> in plasma of RhD‐negative pregnant women—2 years of screening experience from Denmark

Abstract

The high sensitivity, maintained over 2 years, underlines the reliability of routine prenatal fetal RHD screening in RhD-negative pregnant women, specifically at 25 weeks of gestation. The remaining challenges are logistical and are related to program compliance.